Home   »   Media   »   Newsletter Q4 2018

Newsletter Q4 2018

The field of Alzheimer’s research remains frustratingly unchanged, characterized by frequent claims of research breakthroughs, followed by predictable clinical failures.

Watch more

  • Newsletter Q3 2019
  • In our Q1 2017 newsletter, as CEO, I wrote about the reasons why I co-founded Telocyte with Michael; today I reflect on our progress, ...

  • Newsletter Q2 2019
  • The number of people dying from age-related dementias continues to climb. Why? Within the US alone, the CDC points out that the incidence of death...

  • Newsletter Q1 2019
  • Telocyte focuses on Alzheimer’s disease. Once we have engaged in our phase 1 FDA trial, currently slated for 2020, we plan to engage with other age-related diseases...